Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers in collaboration with Sylvester Comprehensive Cancer Center and groups around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies.
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumors; includes vanguard treatment recommendations involving multimodality treatment for high-risk disease.
Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.
Bo (Bonnie) Qin, PhD, researcher and cancer epidemiologist in the Section of Cancer Epidemiology and Health Outcomes at Rutgers Cancer Institute of New Jersey, has received $1.1M from the American Cancer Society to support her research on the impact of lifestyle patterns, social determinants of health, and inflammatory mechanisms on breast cancer survivorship among Black women.
Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a total of $2.6M to support his research on acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that affects both children and adults.
UC Davis Health has adopted a new technology platform, Viz.ai, to help quickly identify patients suspected of having a stroke. The hospital is the first in the Sacramento region to use the platform.
George Raptis, MD, MBA, begins role at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health as director of Oncology Services for the Northern Region of New Jersey.
Today, Memorial Sloan Kettering Cancer Center (MSK), in collaboration with Miami-based creative agency Alma, launched a bilingual public service campaign to promote the importance of routine cancer screenings.
A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.
The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.
For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation.
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, has joined a select number of institutions nationwide that offer a specialized chemotherapy delivery system called hepatic artery infusion (HAI) therapy for patients with liver tumors.
To further support its mission and vision, Rutgers Cancer Institute of New Jersey has modified its leadership structure by elevating two associate director functions to deputy director positions.
The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre.
It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.
February is Cancer Prevention Month. While cancer can feel inevitable, random or out of our control, there are things we can do to reduce cancer risk, from exercise and nutrition to annual screenings.
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.
A new study from UC Davis Health and Oregon Health & Science University reveals significant disparities in dementia care.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Women in low-income areas of the U.S. face a stark rise in cervical cancer incidence and mortality, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.
Eugenia Girda, MD, FACOG, gynecologic oncologist in the Gynecologic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health is lead author of a recent clinical practice statement exploring therapies for cervical cancer.
One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.
The University of Texas MD Anderson Cancer Center will host the 2024 Cancer Neuroscience Symposium, Feb. 28 - Mar. 1, in collaboration the journal Advanced Biology.
Exposure to organophosphate ester flame retardants during pregnancy is linked to premature births, according to new research published in Environmental Health Perspectives.
CRI helped commission a poll of oncologists who say that much more research is required to holistically tackle non-small cell lung cancer.
Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.
In a new article published in Nature Chemistry, Moffitt Cancer Center researchers describe their development of a new reagent that allows a more efficient approach to make sulfoximines, sulfonimidoyl fluorides and sulfonimidamides that may be used in medicines.
20221027104337.jpg&width=400&height=400)
Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium as well as the ASCO Genitourinary Cancers Symposium this month.
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.
UC Davis Health and Kaiser Permanente Division of Research received a $24 million grant from the National Institute on Aging, part of the NIH, to continue the Study of Healthy Aging in African Americans (STAR).
Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% compared to standard therapy. Despite these positive outcomes in event-free survival and overall survival, some patients did not respond well to therapy or relapsed quickly after treatment. Researchers wanted to assess if there were specific tumor characteristics associated with improved outcomes that could better inform treatment selection. Their findings were published today in Nature Medicine.
In a recent article published in Nature Communications, Moffitt Cancer Center researchers, in collaboration with The Tisch Cancer Institute; St. Jude Children’s Research Hospital; the Agency for Science, Technology and Research in Singapore; and the University of Otago in New Zealand, demonstrate that deregulation of a protein called RBFOX2, involved in RNA splicing, contributes to the progression and metastasis of pancreatic cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include insights into the effects of the gut microbiome on remote tumors, a screening strategy for ovarian cancer early detection, a combination approach to overcome PARP inhibitor resistance, further understanding of ferroptosis resistance, a ferroptosis-based strategy for overcoming treatment resistance in acute myeloid leukemia (AML), potential targets for p53 mutations that lead to cancer progression, a signature for more accurately predicting risk in patients with AML given low-intensity treatments, and a prognostic tool to stratify patients with colorectal cancer.
Researchers at Dana-Farber Cancer Institute and the University of Trento, Italy, have developed a blood test, described in Cancer Discovery, that can reliably detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate cancer-adenocarcinoma.
While scientists have made significant progress in understanding the molecular mechanisms leading to melanoma development, it is still unclear how the PTEN protein regulates melanoma progression. In a new study published in Cancer Research, a journal of the American Association for Cancer Research, Moffitt Cancer Center researchers reveal how the antitumor activity of PTEN suppresses the cancer-promoting activity of the FRA1 transcription factor through the AKT signaling pathway.
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.
For the first time ever in New Mexico, doctors at UNM Comprehensive Cancer Center have treated blood cancer patients by transplanting cells from a donor. Late last year, Matthew Fero, MD, FACP, and the Stem Cell and Bone Marrow Transplant team completed the first procedure, known as an allogeneic stem cell transplant.
Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a $500,000 collaborative grant from Gabrielle's Angel Foundation for Cancer Research and The Mark Foundation for Cancer Research.
In a new case study published in New England Journal of Medicine Catalyst’s January 2024 issue, UC Davis Health shared a road map for increasing workforce diversity across the health care industry.
• Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters
High levels of folic acid or vitamin B12 deficiency can affect fetal brain development in mice, according to a new study from researchers at the University of California, Davis.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
